Cover Image
市場調查報告書

乾癬:現在、未來市場參與企業

Psoriasis - Current and Future Players

出版商 GlobalData 商品編碼 277051
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
乾癬:現在、未來市場參與企業 Psoriasis - Current and Future Players
出版日期: 2016年04月13日 內容資訊: 英文 86 Pages
簡介

本報告提供全球乾癬的相關市場上現有/新加入企業相關分析,整體市場的未來展望和促進、阻礙因素,現在、未來的競爭趨勢,主要企業簡介(企業概要,企業發展,財務狀況,SWOT分析)等調查。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 市場預測
    • 促進、阻礙因素:全球市場課題

第4章 現在、未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Johnson. Johnson
    • AbbVie
    • Amgen
    • Novartis
    • Pfizer
    • Eli Lilly
    • Merck
    • LEO Pharma
    • Celgene
    • Can-Fite Biopharma

第5章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC1044FPR

GlobalData has released its pharma report, "Psoriasis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Psoriasis Market. The report identifies and analyses the key companies shaping and driving the global Psoriasis market. The report provides insight into the competitive Psoriasis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Psoriasis
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Psoriasis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Psoriasis market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Psoriasis market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers. Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Johnson. Johnson
    • 4.3.2. AbbVie
    • 4.3.3. Amgen
    • 4.3.4. Novartis
    • 4.3.5. Pfizer
    • 4.3.6. Eli Lilly
    • 4.3.7. Merck
    • 4.3.8. LEO Pharma
    • 4.3.9. Celgene
    • 4.3.10. Can-Fite Biopharma

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed Psoriasis Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Generic Erosion
    • 5.4.8. Pricing of Pipeline agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. Primary Research. Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Author
    • 5.7.2. Reviewer
    • 5.7.3. Epidemiologist
    • 5.7.4. Global Director of Therapy Analysis and Epidemiology
    • 5.7.5. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for Psoriasis, 2014-2024
  • Table 2: Global Psoriasis Market - Drivers and Barriers, 2014-2024
  • Table 3: Key Companies in the Psoriasis Market, 2014
  • Table 4: J&J's Psoriasis Portfolio Assessment, 2015
  • Table 5: J&J's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 6: AbbVie's Psoriasis Portfolio Assessment, 2015
  • Table 7: AbbVie's Psoriasis SWOT Analysis, 2015
  • Table 8: Amgen's Psoriasis Portfolio Assessment, 2015
  • Table 9: Amgen's Psoriasis SWOT Analysis, 2015
  • Table 10: Novartis's Psoriasis Portfolio Assessment, 2015
  • Table 11: Novartis' Psoriasis SWOT Analysis, 2015
  • Table 12: Pfizer's Psoriasis Portfolio Assessment, 2015
  • Table 13: Pfizer's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 14: Eli Lilly's Psoriasis Portfolio Assessment, 2015
  • Table 15: Eli Lilly's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 16: Merck's Psoriasis Portfolio Assessment, 2015
  • Table 17: Merck's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 18: LEO Pharma's Psoriasis Portfolio Assessment, 2015
  • Table 19: LEO Pharma's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 20: Celgene's Psoriasis Portfolio Assessment, 2015
  • Table 21: Celgene's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 22: Celgene's Psoriasis Portfolio Assessment, 2015
  • Table 23: Celgene's Psoriasis Portfolio SWOT Analysis, 2015
  • Table 24: Key Launch Dates
  • Table 25: Key Patent Expiries
  • Table 26: Key Launch Dates
  • Table 27: Physicians Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for Psoriasis by Region, 2014-2024
  • Figure 2: Company Portfolio Gap Analysis in Psoriasis, 2014-2024
Back to Top